Vamil Diva

Five analysts have downgraded Teva Pharmaceuticals Industries Ltd (ADR) (NYSE: TEVA) since it reported its second-quarter earnings on Thursday before the market opened. Credit Suisse’s Vamil Diva is one of them, moving from Outperform to Neutral with a price target dropped from $39 to $25....